ONX-0914, Immunoproteasome Inhibitor


Catalog No. size PriceQuantity
M60112-2S 2 mg solid $139
M60112-10S 10mg solid $556

Description

Product Information
Molecular Weight: 580.67
Formula: C31H40N4O7
Purity: ≥98%
CAS#: 960374-59-8
Solubility: DMSO up to 100 mM
Chemical Name: (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

 

Biological Activity:

 

ONX-0914 is an immunoproteasome inhibitor. It selectively inhibits low–molecular mass polypeptide-7 (LMP7, encoded by Psmb8), the chymotrypsin-like subunit of the immunoproteasome, with an IC50 < 100 nM. It blocked presentation of LMP7-specific, MHC-I–restricted antigens in vitro and in vivo with minimal cross-reactivity for the constitutive proteasome. Selective inhibition of LMP7 by ONX-0914 blocked production of interleukin-23 (IL-23) by activated monocytes and interferon-gamma and IL-2 by T cells. In mouse models of rheumatoid arthritis and lupus, ONX-0914 treatment reversed signs of disease and resulted in reductions in cellular infiltration, cytokine production and autoantibody levels at well-tolerated doses. ONX 0914 is a good chemical probe to reveal a unique role for LMP7 in controlling pathogenic immune responses and provide a therapeutic rationale for autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus.

 


How to Use:

 

 

  • In vitro: ONX-0914 was used at 0.1-0.3 µM in vitro and in cellular assays.
  • In vivo: ONX-0914 was dosed to mice by either intravenous or subcutaneous administration at 2-10 mg/kg once a day for 5 days.

 

 

 


Reference:

 

  1. Muchamuel T, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. (2009) Nat Med. 15(7):781-7.
  2. Basler M, et al. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. (2010) J Immunol. 185(1):634-41.
  3. Huber EM, et al. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. (2012) Cell. 148(4):727-38.
  4. Kalim KW, et al. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. (2012) J Immunol. 189(8):4182-93.

 

 



Products are for research use only. Not for human use.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed